BioEcho develops single-spin and 96/384-well kits based on the patent pending single-step EchoLUTION nucleic acid extraction process. Highly superior to the commonly used silica-based solutions (bind-wash-elute), the isolated inhibitor-free RNA/DNA is detected with increased sensitivity. Furthermore, the whole procedure is up to 20-fold faster: Washing steps are not required, saving time, costs and plastic waste. Due to the expertise of its founders and employees, BioEcho also uses its know-how to support diagnostic or pharma companies with specialized scientific knowledge. Especially in times like these, BioEcho helps to accelerate accurate tests on certain RNA/DNA viruses such as SARS-CoV-2.

Precision Oncology – High-Precision Radionuclide Therapy is a promising, new generation of targeted molecular therapy in which the smallest amounts of medical radioactivity find their way through the bloodstream specifically to the tumour cells for diagnosis and treatment of cancer.

Sino Biological is a world-leading manufacturer of recombinant protein and antibody reagents for life science researches and drug discoveries. In response to the current COVID-19 pandemic, we have developed a series of active reagents (virus proteins, antibodies, and pseudoviruses) to facilitate serologic tests and anti-viral drug developments.

Gene therapy, considered to be the most efficient and sometimes only treatment option for many severe and life-threatening diseases, is shifting to more common indications with higher numbers of patients including Parkinson’s and Alzheimer’s disease. This is where the new ELEVECTA^® AAV producer cell lines come into play. ELEVECTA^® is a revolutionary technology that enables viral vector manufacturing in an industry-standard, scalable suspension format.

BioEcho develops single-spin and 96/384-well kits based on the proprietary single-step EchoLUTION nucleic acid extraction process. Highly superior to the commonly used Silica-based solutions (bind-wash-elute), the whole procedure is extremely fast. Washing steps are not required and the isolated inhibitor-free RNA/DNA is detected with increased sensitivity. Due to the expertise of its founders and employees, BioEcho also uses their know-how to support companies with limited research capacities or specialized scientific knowledge. Especially in times like these, BioEcho helps to accelerate accurate tests on certain RNA/DNA viruses or pathogens.